What is the deadline for submitting a stockholder proposal or director nomination for the next annual meeting of stockholders?
Stockholders wishing to make a director nomination, or bring another proposal, before the 2025 annual meeting of stockholders (but not include it in the Company’s proxy materials for that meeting) must provide written notice of such proposal to the Corporate Secretary at the Company’s principal executive offices at 5956 Sherry Lane Suite 700, Dallas, TX 75225, Attention: Secretary. Such proposals must be received not earlier than the 150th day nor later than 5:00 p.m. Eastern Time on the 120th day prior to the first anniversary of the date of the proxy statement for the preceding year’s annual meeting. Accordingly, to be timely for the next annual meeting, we generally must receive advance notice of the nomination or proposal no earlier than February 5, 2025 and no later than 5:00 p.m. Eastern Time on March 7, 2025. Any stockholder proposal or director nomination must comply with the other provisions of the Bylaws and be submitted in writing to the Secretary of the Company at the Company’s principal executive offices.
Stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for inclusion in the Company’s proxy statement and form of proxy for the Company’s next annual meeting of stockholders must be received at the Company’s principal executive offices and must be submitted no later than March 7, 2025.
In addition, stockholders who intend to solicit proxies in support of director nominees, other than the Company’s nominees, must provide notice in compliance with the universal proxy rules that sets forth the information required by Rule 14a-19 under the Exchange Act, including providing the notice required under Exchange Act Rule 14a-19(b) no later than June 2, 2025.
We have not yet determined the date of our next annual meeting of stockholders. Prior to such annual meeting, we will announce the date of the annual meeting and any dates specified above to the extent required by Rule 14a-5 under the Exchange Act.
Whom should I contact with other questions?
If you have additional questions about this Proxy Statement or the Special Meeting, or if you would like additional copies of this Proxy Statement, please contact Okapi Partners LLC, 1212 Avenue of the Americas, 17th Floor, New York, NY 10036, banks and brokerage firms, please call: (212) 297-0720, shareholders and all others call toll-free: (888) 785-6707 or send an email to info@okapipartners.com.
GENERAL OVERVIEW
The purpose of Proposal 1, the Reverse Stock Split, is to maintain the listing of our Common Stock on The Nasdaq Global Market (“Nasdaq”).
The Company’s Nasdaq Listing Deficiencies
As previously reported, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires us to maintain a minimum bid price per share of $1.00, such that the share price of the Common Stock does not close below $1.00 for 30 consecutive business days (the “Nasdaq Minimum Bid Price Rule”). This listing deficiency has a 180-day period for regaining compliance, which 180-day period ends on May 6, 2025.
The Company has not yet regained compliance with the Nasdaq Minimum Bid Price Rule, and if the Company is not able to regain compliance with the Nasdaq Minimum Bid Price Rule by May 6, 2025, the Company expects to receive notice from Nasdaq that the Common Stock is subject to delisting on this basis. The Company may regain compliance with the Nasdaq Minimum Bid Price Rule if, by May 6, 2025, the closing bid price of the Common Stock is at least $1.00 for a minimum of ten consecutive trading days. If the Company cannot demonstrate compliance with the Nasdaq Minimum Bid Price Rule by May 6, 2025, the Common Stock will be subject to delisting, pending an appeal, if any, to an independent hearings panel.
The Common Stock bid price has come under significant downward pressure since August 2024 when the Company announced its intention to redeem, and has redeemed, shares of its Series A Preferred Stock, $0.001 par value per share (“Series A Preferred Stock”) and Series A1 Preferred Stock, $0.001 par value per